A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

MLA

Hamza Hasan, et al. “A Phase II Randomized Trial of RAdium-223 Dichloride and SABR Versus SABR for OligomEtastatic Prostate CaNcerS (RAVENS).” BMC Cancer, vol. 20, no. 1, June 2020, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12885-020-07000-2.

APA

Hamza Hasan, Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan, Ana P. Kiess, Shirl Dipasquale, James Huang, Terry Caldwell, Jessica Leitzel, Danielle Wendler, Hao Wang, Elizabeth Thompson, Jonathan Powell, Sara Dudley, Curtiland Deville, Stephen C. Greco, Daniel Y. Song, … Phuoc T. Tran. (2020). A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 20(1), 1–13. https://doi.org/10.1186/s12885-020-07000-2

Chicago

Hamza Hasan, Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan, Ana P. Kiess, et al. 2020. “A Phase II Randomized Trial of RAdium-223 Dichloride and SABR Versus SABR for OligomEtastatic Prostate CaNcerS (RAVENS).” BMC Cancer 20 (1): 1–13. doi:10.1186/s12885-020-07000-2.